239 related articles for article (PubMed ID: 21631410)
1. Fatty acid amide hydrolase inhibitors--progress and potential.
Khanna IK; Alexander CW
CNS Neurol Disord Drug Targets; 2011 Aug; 10(5):545-58. PubMed ID: 21631410
[TBL] [Abstract][Full Text] [Related]
2. Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system.
Cravatt BF; Lichtman AH
Curr Opin Chem Biol; 2003 Aug; 7(4):469-75. PubMed ID: 12941421
[TBL] [Abstract][Full Text] [Related]
3. Fatty acid amide hydrolase: biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol, palmitoylethanolamide, and oleamide.
Fowler CJ; Jonsson KO; Tiger G
Biochem Pharmacol; 2001 Sep; 62(5):517-26. PubMed ID: 11585048
[TBL] [Abstract][Full Text] [Related]
4. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells.
Di Marzo V; Melck D; Orlando P; Bisogno T; Zagoory O; Bifulco M; Vogel Z; De Petrocellis L
Biochem J; 2001 Aug; 358(Pt 1):249-55. PubMed ID: 11485574
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation.
Fegley D; Gaetani S; Duranti A; Tontini A; Mor M; Tarzia G; Piomelli D
J Pharmacol Exp Ther; 2005 Apr; 313(1):352-8. PubMed ID: 15579492
[TBL] [Abstract][Full Text] [Related]
6. Modifications of the ethanolamine head in N-palmitoylethanolamine: synthesis and evaluation of new agents interfering with the metabolism of anandamide.
Vandevoorde S; Jonsson KO; Fowler CJ; Lambert DM
J Med Chem; 2003 Apr; 46(8):1440-8. PubMed ID: 12672243
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of FAAH confers increased stem cell migration via PPARα.
Wollank Y; Ramer R; Ivanov I; Salamon A; Peters K; Hinz B
J Lipid Res; 2015 Oct; 56(10):1947-60. PubMed ID: 26263913
[TBL] [Abstract][Full Text] [Related]
8. Fatty acid amide hydrolase inhibition normalises bladder function and reduces pain through normalising the anandamide/palmitoylethanolamine ratio in the inflamed bladder of rats.
Charrua A; Matos R; Oliveira R; Marczylo T; Nagy I; Cruz F
Naunyn Schmiedebergs Arch Pharmacol; 2020 Feb; 393(2):263-272. PubMed ID: 31522241
[TBL] [Abstract][Full Text] [Related]
9. Endocannabinoids in the intact retina: 3 H-anandamide uptake, fatty acid amide hydrolase immunoreactivity and hydrolysis of anandamide.
Glaser ST; Deutsch DG; Studholme KM; Zimov S; Yazulla S
Vis Neurosci; 2005; 22(6):693-705. PubMed ID: 16469181
[TBL] [Abstract][Full Text] [Related]
10. Endocannabinoid metabolism in the absence of fatty acid amide hydrolase (FAAH): discovery of phosphorylcholine derivatives of N-acyl ethanolamines.
Mulder AM; Cravatt BF
Biochemistry; 2006 Sep; 45(38):11267-77. PubMed ID: 16981687
[TBL] [Abstract][Full Text] [Related]
11. Lipid droplets are novel sites of N-acylethanolamine inactivation by fatty acid amide hydrolase-2.
Kaczocha M; Glaser ST; Chae J; Brown DA; Deutsch DG
J Biol Chem; 2010 Jan; 285(4):2796-806. PubMed ID: 19926788
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo.
Lichtman AH; Hawkins EG; Griffin G; Cravatt BF
J Pharmacol Exp Ther; 2002 Jul; 302(1):73-9. PubMed ID: 12065702
[TBL] [Abstract][Full Text] [Related]
13. FAAH and anandamide: is 2-AG really the odd one out?
Di Marzo V; Maccarrone M
Trends Pharmacol Sci; 2008 May; 29(5):229-33. PubMed ID: 18394720
[TBL] [Abstract][Full Text] [Related]
14. Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase.
van der Stelt M; van Kuik JA; Bari M; van Zadelhoff G; Leeflang BR; Veldink GA; Finazzi-Agrò A; Vliegenthart JF; Maccarrone M
J Med Chem; 2002 Aug; 45(17):3709-20. PubMed ID: 12166944
[TBL] [Abstract][Full Text] [Related]
15. Fatty acid amide hydrolase inhibition enhances the anti-allodynic actions of endocannabinoids in a model of acute pain adapted for the mouse.
Palmer JA; Higuera ES; Chang L; Chaplan SR
Neuroscience; 2008 Jul; 154(4):1554-61. PubMed ID: 18541380
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors.
Dickason-Chesterfield AK; Kidd SR; Moore SA; Schaus JM; Liu B; Nomikos GG; Felder CC
Cell Mol Neurobiol; 2006; 26(4-6):407-23. PubMed ID: 16736384
[TBL] [Abstract][Full Text] [Related]
17. Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).
Lodola A; Castelli R; Mor M; Rivara S
Expert Opin Ther Pat; 2015; 25(11):1247-66. PubMed ID: 26413912
[TBL] [Abstract][Full Text] [Related]
18. The fatty acid amide hydrolase (FAAH).
Deutsch DG; Ueda N; Yamamoto S
Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):201-10. PubMed ID: 12052036
[TBL] [Abstract][Full Text] [Related]
19. Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors.
Melis M; Pillolla G; Luchicchi A; Muntoni AL; Yasar S; Goldberg SR; Pistis M
J Neurosci; 2008 Dec; 28(51):13985-94. PubMed ID: 19091987
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of fatty acid amides in the carrageenan-induced paw edema model.
Wise LE; Cannavacciulo R; Cravatt BF; Martin BF; Lichtman AH
Neuropharmacology; 2008 Jan; 54(1):181-8. PubMed ID: 17675189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
